For the quarter ending 2025-09-30, AQST had $68,527K increase in cash & cash equivalents over the period. -$12,884K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -15,446 | -36,478 |
| Depreciation, amortization, and impairment | 139 | 279 |
| Gain on contract termination | 0 | 0 |
| Share-based compensation | 2,777 | 3,471 |
| Amortization of debt issuance costs and discounts | 2,748 | 5,498 |
| Other, net | -11 | 11 |
| Trade and other receivables, net | -63 | 4,476 |
| Inventories | -241 | 2,081 |
| Prepaid expenses and other assets | 1,721 | -3,104 |
| Accounts payable | -1,306 | 1,582 |
| Accrued expenses and other liabilities | 118 | -2,176 |
| Deferred revenue | -273 | -26 |
| Net cash used for operating activities | -12,649 | -31,314 |
| Capital expenditures | 235 | 242 |
| Net cash used for investing activities | -235 | -242 |
| Proceeds from common stock issued under public equity offering-At The Market Offering | -9 | 21,236 |
| Proceeds from common stock issued under public equity offering-Public Equity Offering | 79,728 | 0 |
| Proceeds from shares issued under employee stock purchase plan | 0 | 50 |
| Proceeds from exercise of stock options, net | 339 | 7 |
| Proceeds from exercise of warrants, net | 1,430 | - |
| Repayment of debt principal including lease liabilities | 7 | 14 |
| Payments for royalty obligations | 0 | 11 |
| Payments for taxes on share-based compensation | 70 | 722 |
| Net cash provided by financing activities | 81,411 | 20,546 |
| Net increase in cash and cash equivalents | 68,527 | -11,010 |
| Cash and cash equivalents at beginning of period | 71,546 | - |
| Cash and cash equivalents at end of period | 129,063 | - |
Aquestive Therapeutics, Inc. (AQST)
Aquestive Therapeutics, Inc. (AQST)